Given the importance of GC resistance in ALL and the comparatively poor clinical outcomes for patients with CRLF2 overexpression, we hypothesized that the aberrant signal transduction associated with CRLF2 overexpression might contribute to suboptimal responses to GC therapy. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.